Magazine Article | October 30, 2020

Companies To Watch: Ridgeback Biotherapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses

SNAPSHOT

Ridgeback Biotherapeutics is a private company developing antivirals for untreated and pandemic diseases, with support from partnerships and public funding. It is currently partnering with Merck in Phase 2 development of a ribonucleoside analog, coded MK-4482, an oral drug for treating COVID-19 infection by inhibiting viral replication. Another lead product, ansuvimab, is under priority review by the FDA for treating Ebola.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: